Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06351371
What this trial is testing

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT04172675
What this trial is testing

Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Who this might be right for
Urinary Bladder Neoplasms
Janssen Research & Development, LLC 107
Not applicableUnknownNCT04339933
What this trial is testing

Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma

Who this might be right for
Bladder Cancer
Ho Kyung Seo 92
Large-scale testing (Phase 3)Study completedNCT02965378
What this trial is testing

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene Amplification+5 more
SWOG Cancer Research Network 43
Testing effectiveness (Phase 2)Looking for participantsNCT06995677
What this trial is testing

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT05544552
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Who this might be right for
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaSolid Tumor+11 more
Tyra Biosciences, Inc 310
Testing effectiveness (Phase 2)Study completedNCT02272998
What this trial is testing

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Who this might be right for
Malignant Neoplasm
Sameek Roychowdhury 22
Testing effectiveness (Phase 2)UnknownNCT04096417
What this trial is testing

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene Translocation+16 more
Academic and Community Cancer Research United 14
Testing effectiveness (Phase 2)Ended earlyNCT01732107
What this trial is testing

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Who this might be right for
Bladder Cancer
Noah Hahn, M.D. 13
Testing effectiveness (Phase 2)Ended earlyNCT03827850
What this trial is testing

FGFR Inhibitor in FGFR Dysregulated Cancer

Who this might be right for
Lung CancerNSCLCPulmonary Neoplasm+2 more
Lung Cancer Group Cologne 22
Testing effectiveness (Phase 2)Ended earlyNCT03822117
What this trial is testing

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Who this might be right for
Solid Tumor Malignancy
Incyte Corporation 111
Testing effectiveness (Phase 2)Study completedNCT04233567
What this trial is testing

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmCholangiocarcinomaMetastatic Malignant Solid Neoplasm+1 more
Sameek Roychowdhury 17
Testing effectiveness (Phase 2)Looking for participantsNCT04962867
What this trial is testing

NCCH2006/MK010 Trial (FORTUNE Trial)

Who this might be right for
Advanced or Recurrent Solid TumorsFGFR Gene Alterations
National Cancer Center, Japan 75
Testing effectiveness (Phase 2)UnknownNCT05997459
What this trial is testing

A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant

Who this might be right for
Locally Advanced Unresectable Gastric Cancer
Sun Yat-sen University 23
Early research (Phase 1)Looking for participantsNCT06915753
What this trial is testing

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Who this might be right for
Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult+8 more
Tyra Biosciences, Inc 125
Testing effectiveness (Phase 2)Study completedNCT01831726
What this trial is testing

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Who this might be right for
Tumor Pathway Activations Inhibited by Dovitinib
Novartis Pharmaceuticals 80